Angiogenesis Foundation
News & MediaFDA Grants Priority Review of Antiangiogenic Agent Aflibercept for Treatment of Diabetic Retinopathy in DME Patients
The U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). Under the...
Aflibercept injection shown to be superior to bevacizumab and ranibizumab in visual gains for DME patients
In the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA® (aflibercept) Injection demonstrated a significantly greater...
Antiangiogenic agent bevacizumab gets FDA approval for treating platinum-resistant recurrent ovarian cancer
The U.S. Food and Drug Administration (FDA) approved antiangiogenic agent bevacizumab (Avastin®) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from the Phase III AURELIA...
Patient Forum and Dinner, “Antiangiogenesis: Answer to Cancer”
On October 14, the Angiogenesis Foundation hosted a Patient Forum and Dinner, "Antiangiogenesis: Answer to Cancer," at the Westin Boston Waterfront Hotel, where it convened a diverse group of patients, scientists, caregivers, and healthcare practitioners to celebrate...
Anti-VEGF Agent Aflibercept FDA Approved for Treating Macular Edema Following Retinal Vein Occlusion (RVO)
The U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes Macular Edema following Branch Retinal Vein Occlusion (BRVO) in addition to the...
Antiangiogenic Agent Aflibercept Approved in Japan for Treating Myopic Choroidal Neovascularization (CNV)
Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for EYLEA® (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV). EYLEA has already been approved...
FDA Approves Bevacizumab Plus Chemotherapy for Cervical Cancer
The U.S. Food and Drug Administration, on August 14, 2014 approved bevacizumab solution for intravenous infusion (Avastin®, Genentech, Inc.) for the treatment of persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or...
Anti-VEGF agent aflibercept gets EU Approval for Treatment of Diabetic Macular Edema (DME)
Aflibercept (EYLEA) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer Healthcare plans to launch EYLEA in DME in the EU this quarter. EYLEA was approved in the United States for the...
FDA approves anti-VEGF agent aflibercept for treating Diabetic Macular Edema (DME)
The U.S. Food and Drug Administration (FDA) has approved aflibercept (EYLEA®) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly...
FDA grants antiangiogenic agent bevacizumab priority review for cervical cancer
The U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) from Genentech and granted Priority Review for antiangiogenic agent bevacizumab (Avastin®) plus chemotherapy for the treatment of women with persistent,...
Vascular endothelium found to play critical role in the brain’s regulation of blood flow
In a new study published online in the Journal of the American Heart Association June 12, 2014, researchers at Columbia Engineering report that they have identified a new component of the biological mechanism that controls blood flow in the brain. Led by Elizabeth M....
Anti-VEGF agent lenvatinib significantly improves progression-free survival in thyroid cancer patients
A new oral drug called lenvatinib looks promising as a treatment for a type of thyroid cancer that resists standard radiation, according to a later-stage clinical trial. "We are confident that, based on our findings, lenvatinib will eventually become a standard...
Antiangiogenic agent bevacizumab gets EU recommendation for treating platinum-resistant recurrent ovarian cancer
Bevacizumab (Avastin) becomes the first biologic medicine to be recommended for treating platinum-resistant recurrent ovarian cancer, the most challenging form of the disease to treat with only a quarter of patients surviving beyond five years. The CHMP's...
European commission recommends approval of anti-VEGF agent aflibercept for treatment of diabetic macular edema
Aflibercept (EYLEA®) injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in...
New antiangiogenic agent TAS-102 improves overall survival in patients with refractory mCRC
Treatment with the investigational oral agent TAS-102 significantly improved overall survival (OS) in a phase III trial for patients with heavily pretreated metastatic colorectal cancer (mCRC), prompting Taiho Oncology, the company developing the drug, to prepare a...
Ramucirumab is the first antiangiogenic agent to be approved for treatment of advanced stomach cancer
On April 21, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza) for use as a single agent for the treatment of patients with advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after...
Journal of Clinical Oncology Publishes Phase III Results (PISCES) Comparing Patient Treatment Preferences for Antiangiogenic Agents for Advanced Kidney Cancer
Data from the first patient preference study in advanced renal cell carcinoma are published today in the Journal of Clinical Oncology1. The study, known as PISCES, showed more patients expressed a preference for continuing treatment with Votrient® (pazopanib) than...
Antiangiogenic Agent Ranibizumab Approved in Japan for Treatment of Diabetic Macular Edema
Swiss pharma giant Novartis AG announced that Lucentis (ranibizumab) has been approved by Japanese regulatory bodies for a fourth indication: to treat patients with diabetic macular edema or DME, a main cause of vision loss among patients with diabetes. Laser therapy,...
Discovery: Tumor blood vessels can make cancer more aggressive and resistant to chemotherapy
Blood vessels have been thought to be important to cancer because of the nutritious oxygen they provide to growing tumors. But now, researchers at Weill Cornell Medical College have discovered that the cells that line the blood vessels of tumors play a much more...
New Antiangiogenic Treatment (Cabozantinib) Approved in the European Union for Treatment of Medullary Thyroid Carcinoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 25, 2014-- Exelixis, Inc.(NASDAQ:EXEL) today announced that the European Commission has approved COMETRIQ® (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or...
Folkman’s Legacy of Bold and Creative Thinking Endures
Asked why Judah Folkman, MD, ranks among the greatest modernday medical pioneers, Robert S. Langer, ScD, recalled the time he told Folkman the gist of a new paper involving ultrasound. Folkman asked why heat from the ultrasound wouldn't cause harm, and Langer...
NHS Cancer Drug Fund to cover bevacizumab for women with cervical cancer
Women in England who are dying of cervical cancer are to receive a drug that could extend their lives by as much as four months. Women with advanced cervical cancer will be able to get Avastin, which is also known as bevacizumab, after NHS England decided to fund...
Positive clinical trial results for combination antiangiogenic and vascular targeting therapy in recurrent ovarian cancer
SOUTH SAN FRANCISCO, Calif., March 11, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating...
Ramucirumab improves survival in clinical trial for lung cancer
An experimental cancer drug developed by Eli Lilly and Co significantly improved survival rates in lung cancer patients. The drug has already been shown to be successful in treating stomach cancer. Ramucirumab works by blocking angiogenesis, the formation of blood...